Cytisinicline

Smoking cessation

Manufacturer: Achieve Life Sciences
Regulatory submission: NDA resubmission planned for the fourth quarter of 2026
Launch: Anticipated after potential approval in the first half of 2027
Last updated: September 19, 2026

Section

Economic information and modeling report Budget impact model Results

Scenario analyses

1 evidence topic · 1 source

Alternative course prices: eligible population treatable below the annual threshold

Course price	Eligible population
“$1,300”	“18.4%”
“$2,000”	“11.4%”
“$2,700”	“8.1%”